Hostname: page-component-669899f699-vbsjw Total loading time: 0 Render date: 2025-04-29T13:46:29.721Z Has data issue: false hasContentIssue false
  • English
  • Français

The PHARMO System

Published online by Cambridge University Press:  07 November 2014

Ron M.C. Herings
Ron M.C. Herings*
Affiliation:
Dr. Herings is associate professor of pharmacoepidemiology at, Utrecht Universityand director of the PHARMO Institute in Utrecht, the Netherlands.
Get access Rights & Permissions [Opens in a new window]

Abstract

Pharmacoepidemiology, the study of the effects of drugs in large numbers of people, is a relatively new discipline that applies the methods of epidemiology to clinical pharmacology. Premarketing clinical trials remain the only way to scientifically determine whether a drug is causally effective, yet these trials do not provide information that allows for estimates about rare, late, or off-label toxicities associated with the drug in question. Increasing concern about common and debilitating adverse effects of medications has highlighted the need for enhanced postmarketing surveillance to follow up on clinical trials. There is a further concern regarding the broader issue of the risk-benefit ratio of certain medications. Computerized databases are a good source of information on which to lay the foundations of postmarketing research. A system of cross-linked computerized medical records may better enable researchers and physicians to realistically monitor postmarketing safety and incorporate monitoring benefits. The same research could also elucidate the net public health effect of regulatory decisions. The Veterans Affairs database in the United States and PHARMO in the Netherlands may represent good models on which to base future postmarketing surveillance studies.

In this expert roundtable supplement, Brian L. Strom, MD, provides an overview of the appropriate use of large computer databases in pharmacoepidemiology studies. Philip Wang, MD, DrPH, discusses the advantages of pharmacoepidemiologic studies over clinical trials in correctly detecting drug safety issues. Francesca Cunningham, PharmD, reviews a large computer database that is currently in use within the VA healthcare system, and Ron M.C. Herings, PharmD, PhD, discusses the development of the PHARMO system in the Netherlands.

Type
Research Article
Information
CNS Spectrums , Volume 12 , Issue S16 , 2007 , pp. 14 - 17
Copyright
Copyright © Cambridge University Press 2007

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Article purchase

Temporarily unavailable

References

1.Herings, RM, Bakker, A, Stricker, BH, Nap, G. Pharmaco-morbidity linkage: a feasibility study comparing morbidity in two pharmacy based exposure cohorts. J Epidemiol Community Health. 1992;46(2):136–140.Google Scholar
2.Herings, RM, Stricker, BH, de Boer, A, Bakker, A, Sturmans, F. Benzodiazepines and the risk of falling leading to femur fractures. Dosage more important than elimination half-life. Arch Intern Med. 1995;155(16):1801–1807.Google Scholar
3.Herings, RM, de Boer, A, Stricker, BH, Leufkens, HG, Porsius, A. Hypoglycaemia associated with use of inhibitors of angiotensin converting enzyme. Lancet. 1995;345(8959):1195–1198.Google Scholar
4.Herings, RM, Urquhart, J, Leufkens, HG. Venous thromboembolism among new users of different oral contraceptives. Lancet. 1999;354(9173):127–128.Google Scholar
5.Schillevoort, I, de Boer, A, Herings, RM, Roos, RA, Jansen, PA, Leufkens, HG. Risk of extrapyramidal syndromes with haloperidol, risperidone, or olanzapine. Ann Pharmacother. 2001;35(12):1517–1522.Google Scholar
6.Meijer, WE, Heerdink, ER, Nolen, WA, Herings, RMC, Leufkens, HGM, Egberts ACG. Association of risk of abnormal bleeding with degree of serotonin reuptake inhibition by antidepressants. Arch Int Med. 2004;164:2367–2370.Google Scholar
7.Herings, RM, Erkens, JA. Increased suicide attempt rate among patients interrupting use of atypical antipsychotics. Pharmacoepidemiol Drug Saf. 2003;12(5):423–424.Google Scholar
8.Gibbons, RD, Hendricks, C, Kwan, H, et al.Early evidence on the effects of the FDA black box warning on SSRI. Prescriptions and suicide in children and adolescents. Am J Psychiatry. 2007. In Press.Google Scholar